


1. A compound of formula (I)



Formula (I)

for use in the treatment of a cancer, wherein said cancer is treated by modulating an immune response comprising a reactivation of the immune system in the tumor;

wherein said compound is optionally used in combination with one or more chemotherapy agents and / or radiotherapy and / or targeted therapy;

wherein in compounds of the formula (I)

(R¹)_n represents one, two or three optional substituents on the phenyl ring, wherein said substituents are independently selected from (C₁₋₃)alkyl, (C₁₋₃)alkoxy, -S-(C₁₋₃)alkyl, halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy, cyano, hydroxy, nitro, -CO-O-(C₁₋₃)alkyl, -NR^{N7}R^{N8} wherein R^{N7} and R^{N8} independently represent hydrogen or (C₁₋₄)alkyl, or R^{N7} and R^{N8} together with the nitrogen to which they are attached form a 4- to 6-membered carbocyclic ring;


R³ represents hydrogen, methyl or trifluoromethyl;

R^{4a} and R^{4b} independently represent hydrogen, methyl, or R^{4a} and R^{4b} together with the carbon atom to which they are attached represent a cycloprop-1,1-diyl group;


R^{5a} and R^{5b} independently represent hydrogen, methyl, or R^{5a} and R^{5b} together with the carbon atom to which they are attached represent a cycloprop-1,1-diyl group;

Ar¹ represents

- phenyl, or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl independently is mono-, di- or tri-substituted, wherein the substituents are independently selected from
 - (C₁₋₆)alkyl;
 - (C₁₋₄)alkoxy;
 - (C₁₋₃)fluoroalkyl, wherein said (C₁₋₃)fluoroalkyl is optionally substituted with hydroxy;
 - (C₁₋₃)fluoroalkoxy;
 - halogen;
 - cyano;
 - (C₃₋₆)cycloalkyl, wherein said (C₃₋₆)cycloalkyl is unsubstituted or mono-substituted with amino;
 - (C₄₋₆)cycloalkyl containing a ring oxygen atom, wherein said (C₄₋₆)cycloalkyl containing a ring oxygen atom is unsubstituted or mono-substituted with hydroxy;

- (C₃₋₆)cycloalkyl-oxy;
- hydroxy;
- -X¹-CO-R⁰¹, wherein
 - X¹ represents a direct bond, (C₁₋₃)alkylene, -O-(C₁₋₃)alkylene-*, -NH-(C₁₋₃)alkylene-*, -S-CH₂-*, -CF₂-, -CH=CH-, -CH≡CH-, -NH-CO-*, -CO-, or (C₃₋₅)cycloalkylene; wherein the asterisks indicate the bond that is linked to the -CO-R⁰¹ group; and
 - R⁰¹ represents
 - -OH;
 - -O-(C₁₋₄)alkyl;
 - -NH-SO₂-R^{S3} wherein R^{S3} represents (C₁₋₄)alkyl, (C₃₋₆)cycloalkyl wherein the (C₃₋₆)cycloalkyl optionally contains a ring oxygen atom, (C₃₋₆)cycloalkyl-(C₁₋₃)alkylene wherein the (C₃₋₆)cycloalkyl optionally contains a ring oxygen atom, (C₁₋₃)fluoroalkyl, or -NH₂;
 - -O-CH₂-CO-R⁰⁴, wherein R⁰⁴ represents hydroxy, or (C₁₋₄)alkoxy, or -N[(C₁₋₄)alkyl]₂;
 - -O-CH₂-O-CO-R⁰⁵, wherein R⁰⁵ represents (C₁₋₄)alkyl or (C₁₋₄)alkoxy;
 - -O-CH₂-CH₂-N[(C₁₋₄)alkyl]₂; or
 - (5-methyl-2-oxo-[1,3]dioxol-4-yl)-methoxy;
- -CO-CH₂-OH;
- ;
 - 2-hydroxy-3,4-dioxo-cyclobut-1-enyl;
 - hydroxy-(C₁₋₄)alkyl;
 - dihydroxy-(C₂₋₄)alkyl;
 - hydroxy-(C₂₋₄)alkoxy;
 - (C₁₋₄)alkoxy-(C₂₋₄)alkoxy;
- -(CH₂)_r-CO-NR^{N3}R^{N4} wherein r represents the integer 0 or 1; and wherein R^{N3} and R^{N4} independently represent hydrogen, (C₁₋₄)alkyl, hydroxy-(C₂₋₄)alkyl, (C₁₋₃)alkoxy-(C₂₋₄)alkyl, or hydroxy;
- -X²-NR^{N1}R^{N2}, wherein X² represents -(CH₂)_m-, wherein m represents the integer 0 or 1; or X² represents -O-CH₂-CH₂-, wherein the asterisk indicates the bond that is linked to the -NR^{N1}R^{N2} group; and wherein
 - R^{N1} and R^{N2} independently represent hydrogen, (C₁₋₄)alkyl, (C₁₋₄)alkoxy-(C₂₋₄)alkyl, (C₃₋₆)cycloalkyl, or (C₂₋₃)fluoroalkyl;
 - or R^{N1} independently represents hydrogen or (C₁₋₄)alkyl, and R^{N2} independently represents -CO-H, -CO-(C₁₋₃)alkyl, -CO-(C₁₋₃)alkylene-OH, or -CO-O-(C₁₋₃)alkyl;


- or R^{N1} and R^{N2} together with the nitrogen to which they are attached form a 4-, 5- or 6-membered saturated ring optionally containing one ring oxygen or ring sulfur atom, wherein said ring is unsubstituted, or mono-substituted with oxo on a ring carbon atom, or disubstituted with oxo on a ring sulfur atom;
- 5 ▪ -NH-CO-NR^{N5}R^{N6} wherein R^{N5} and R^{N6} independently represent hydrogen or (C₁₋₄)alkyl;
- -SO₂-R^{S1} wherein R^{S1} represents hydroxy, (C₁₋₄)alkyl, or -NR^{N7}R^{N8} wherein R^{N7} and R^{N8} independently represent hydrogen or (C₁₋₃)alkyl;
- -S-R^{S2} wherein R^{S2} represents (C₁₋₄)alkyl, or (C₃₋₆)cycloalkyl optionally containing one ring oxygen atom;
- 10 ▪ -(CH₂)_q-HET¹, wherein q represents the integer 0, 1 or 2; and wherein HET¹ represents 5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl, 3-oxo-2,3-dihydro-[1,2,4]oxadiazol-5-yl, or 5-thioxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl;
- -(CH₂)_p-HET, wherein p represents the integer 0 or 1; and wherein HET represents a 5- or 6-membered heteroaryl, wherein said 5- or 6-membered heteroaryl is unsubstituted, or mono- or di-
- 15 substituted, wherein the substituents are independently selected from (C₁₋₄)alkyl, (C₁₋₄)alkoxy, -COOH, hydroxy, hydroxy-(C₁₋₃)alkyl, (C₃₋₅)cycloalkyl optionally containing one ring oxygen atom, or -NR^{N9}R^{N10} wherein R^{N9} and R^{N10} independently represent hydrogen, (C₁₋₃)alkyl, or hydroxy-(C₂₋₄)alkyl;
- or Ar¹ represents 8- to 10-membered bicyclic heteroaryl; wherein said 8- to 10-membered bicyclic heteroaryl independently is unsubstituted, mono-, or di-substituted, wherein the substituents are independently selected
- 20 from (C₁₋₄)alkyl; (C₁₋₄)alkoxy; (C₁₋₃)fluoroalkyl; (C₁₋₃)fluoroalkoxy; halogen; cyano; hydroxy, or -(C₀₋₃)alkylene-COOR^{O2} wherein R^{O2} represents hydrogen or (C₁₋₄)alkyl;
- or Ar¹ represents a group of the structure (Ar-III):



- 25 wherein ring (B) represents a non-aromatic 5- or 6-membered ring fused to the phenyl group, wherein ring (B) comprises one or two heteroatoms independently selected from nitrogen and oxygen; wherein said ring (B) independently is unsubstituted, mono-, or di-substituted, wherein the substituents are independently selected from oxo, (C₁₋₆)alkyl and -(C₀₋₃)alkylene-COOR^{O3} wherein R^{O3} represents hydrogen or (C₁₋₃)alkyl;

or a pharmaceutically acceptable salt thereof.

2. A compound for use according to claim 1, wherein said compound is a compound of formula (II)




Formula (II)

wherein

- 5 **(R¹)_n** represents one, two or three optional substituents on the phenyl ring, wherein said substituents are independently selected from (C₁₋₃)alkyl, (C₁₋₃)alkoxy, -S-(C₁₋₃)alkyl, halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy, cyano, hydroxy, nitro, -CO-O-(C₁₋₃)alkyl, -NR^{N7}R^{N8} wherein **R^{N7}** and **R^{N8}** independently represent hydrogen or (C₁₋₄)alkyl, or **R^{N7}** and **R^{N8}** together with the nitrogen to which they are attached form a 4- to 6-membered carbocyclic ring;
- 10 **R³** represents hydrogen, or methyl;

Ar¹ represents

- a phenyl group of the structure (Ar-I):



(Ar-I)


15 wherein

- **Rᵖ** represents
 - (C₄₋₆)cycloalkyl containing a ring oxygen atom, wherein said (C₄₋₆)cycloalkyl containing a ring oxygen atom is unsubstituted or mono-substituted with hydroxy;
 - hydroxy;
 - 20 ➤ -X¹-CO-Rᵒ¹, wherein
 - **X¹** represents a direct bond, (C₁₋₃)alkylene, -O-(C₁₋₃)alkylene-*, -NH-(C₁₋₃)alkylene-*, -CH=CH-, -NH-CO-*, or (C₃₋₅)cycloalkylene; wherein the asterisks indicate the bond that is linked to the -CO-Rᵒ¹ group; and
 - **Rᵒ¹** represents
 - 25 ▪ -OH;
 - -O-(C₁₋₄)alkyl;
 - -NH-SO₂-R^{S3} wherein **R^{S3}** represents (C₁₋₄)alkyl, (C₃₋₆)cycloalkyl wherein the (C₃₋₆)cycloalkyl optionally contains a ring oxygen atom, (C₃₋₆)cycloalkyl-(C₁₋₃)alkylene

wherein the (C₃₋₆)cycloalkyl optionally contains a ring oxygen atom, (C₁₋₃)fluoroalkyl, or -NH₂;

- -O-CH₂-CO-R^{O4}, wherein R^{O4} represents hydroxy, or (C₁₋₄)alkoxy, or -N[(C₁₋₄)alkyl]₂;
- -O-CH₂-O-CO-R^{O5}, wherein R^{O5} represents (C₁₋₄)alkyl or (C₁₋₄)alkoxy;
- -O-CH₂-CH₂-N[(C₁₋₄)alkyl]₂; or
- (5-methyl-2-oxo-[1,3]dioxol-4-yl)-methoxy-;

5




- 2-hydroxy-3,4-dioxo-cyclobut-1-enyl;
- hydroxy-(C₁₋₄)alkyl;
- 10 ➤ hydroxy-(C₂₋₄)alkoxy;
- -(CH₂)_r-CO-NR^{N3}R^{N4} wherein r represents the integer 0 or 1; and wherein R^{N3} and R^{N4} independently represent hydrogen, (C₁₋₄)alkyl, hydroxy-(C₂₋₄)alkyl, (C₁₋₃)alkoxy-(C₂₋₄)alkyl, or hydroxy;
- -NR^{N1}R^{N2}, wherein R^{N1} independently represents hydrogen or (C₁₋₄)alkyl, and R^{N2} independently represents -CO-H, -CO-(C₁₋₃)alkyl, or -CO-(C₁₋₃)alkylene-OH;
- 15 ➤ -NH-CO-NR^{N5}R^{N6} wherein R^{N5} and R^{N6} independently represent hydrogen or (C₁₋₄)alkyl;
- -SO₂-R^{S1} wherein R^{S1} represents (C₁₋₄)alkyl, or -NR^{N7}R^{N8} wherein R^{N7} and R^{N8} independently represent hydrogen or (C₁₋₃)alkyl;
- -(CH₂)_q-HET¹, wherein q represents the integer 0, 1 or 2; and wherein HET¹ represents 5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl, 3-oxo-2,3-dihydro-[1,2,4]oxadiazol-5-yl, or 5-thioxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl;
- 20 ➤ -(CH₂)_p-HET, wherein p represents the integer 0 or 1; and wherein HET represents a 5-membered heteroaryl, wherein said 5-membered heteroaryl is unsubstituted, or mono- or di-substituted, wherein the substituents are independently selected from (C₁₋₄)alkyl, (C₁₋₄)alkoxy, -COOH, hydroxy, hydroxy-(C₁₋₃)alkyl, (C₃₋₅)cycloalkyl optionally containing one ring oxygen atom, or -NR^{N9}R^{N10} wherein R^{N9} and R^{N10} independently represent hydrogen, (C₁₋₃)alkyl, or hydroxy-(C₂₋₄)alkyl;

25

- R^{m1} represents
 - hydrogen;
 - (C₁₋₆)alkyl;
 - (C₁₋₄)alkoxy;
 - 30 ➤ (C₁₋₃)fluoroalkyl;
 - (C₁₋₃)fluoroalkoxy;
 - halogen;
 - (C₃₋₆)cycloalkyl;
 - (C₃₋₆)cycloalkyl-oxy;

30


- hydroxy;
- hydroxy-(C₂₋₄)alkoxy;
- -X²-NR^{N1}R^{N2}, wherein X² represents a direct bond; or X² represents -O-CH₂-CH₂-, wherein the asterisk indicates the bond that is linked to the -NR^{N1}R^{N2} group; and wherein R^{N1} and R^{N2} independently represent hydrogen, (C₁₋₄)alkyl, or (C₃₋₆)cycloalkyl;
- -S-R^{S2} wherein R^{S2} represents (C₁₋₄)alkyl, or (C₃₋₆)cycloalkyl optionally containing one ring oxygen atom;
- R^{m2} represents hydrogen, methyl, fluoro, or chloro; and
- R^{o1} represents hydrogen; or, in case R^{m2} represents hydrogen, R^{o1} represents hydrogen or fluoro;
- or Ar¹ represents a 5-membered heteroaryl group of the structure (Ar-II):



wherein


- Y represents CR⁸ wherein R⁸ represents hydrogen or halogen; or Y represents N;
- R⁷ represents
 - (C₄₋₆)cycloalkyl containing a ring oxygen atom, wherein said (C₄₋₆)cycloalkyl containing a ring oxygen atom is unsubstituted or mono-substituted with hydroxy;
 - -X¹-CO-R^{o1}, wherein
 - X¹ represents a direct bond, (C₁₋₃)alkylene, -O-(C₁₋₃)alkylene-, -NH-(C₁₋₃)alkylene-, -CH=CH-, -NH-CO-, or (C₃₋₅)cycloalkylene; wherein the asterisks indicate the bond that is linked to the -CO-R^{o1} group; and
 - R^{o1} represents
 - -OH;
 - -O-(C₁₋₄)alkyl;
 - -NH-SO₂-R^{S3} wherein R^{S3} represents (C₁₋₄)alkyl, (C₃₋₆)cycloalkyl wherein the (C₃₋₆)cycloalkyl optionally contains a ring oxygen atom, (C₃₋₆)cycloalkyl-(C₁₋₃)alkylene wherein the (C₃₋₆)cycloalkyl optionally contains a ring oxygen atom, (C₁₋₃)fluoroalkyl, or -NH₂;
 - -O-CH₂-CO-R^{o4}, wherein R^{o4} represents hydroxy, or (C₁₋₄)alkoxy, or -N[(C₁₋₄)alkyl]₂;
 - -O-CH₂-O-CO-R^{o5}, wherein R^{o5} represents (C₁₋₄)alkyl or (C₁₋₄)alkoxy;
 - -O-CH₂-CH₂-N[(C₁₋₄)alkyl]₂; or

- (5-methyl-2-oxo-[1,3]dioxol-4-yl)-methyloxy-;



- 2-hydroxy-3,4-dioxo-cyclobut-1-enyl;
- hydroxy-(C₁₋₄)alkyl;
- 5 ➤ hydroxy-(C₂₋₄)alkoxy;
- -(CH₂)_r-CO-NR^{N3}R^{N4} wherein **r** represents the integer 0 or 1; and wherein **R^{N3}** and **R^{N4}** independently represent hydrogen, (C₁₋₄)alkyl, hydroxy-(C₂₋₄)alkyl, (C₁₋₃)alkoxy-(C₂₋₄)alkyl, or hydroxy;
- -NR^{N1}R^{N2}, wherein **R^{N1}** independently represents hydrogen or (C₁₋₄)alkyl, and **R^{N2}** independently represents -CO-H, -CO-(C₁₋₃)alkyl, or -CO-(C₁₋₃)alkylene-OH;
- 10 ➤ -NH-CO-NR^{N5}R^{N6} wherein **R^{N5}** and **R^{N6}** independently represent hydrogen or (C₁₋₄)alkyl;
- -SO₂-R^{S1} wherein **R^{S1}** represents (C₁₋₄)alkyl, or -NR^{N7}R^{N8} wherein **R^{N7}** and **R^{N8}** independently represent hydrogen or (C₁₋₃)alkyl;
- -(CH₂)_q-HET¹, wherein **q** represents the integer 0, 1 or 2; and wherein **HET¹** represents 5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl, 3-oxo-2,3-dihydro-[1,2,4]oxadiazol-5-yl, or 5-thioxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl;
- 15 ➤ -(CH₂)_p-HET, wherein **p** represents the integer 0 or 1; and wherein **HET** represents a 5-membered heteroaryl, wherein said 5-membered heteroaryl is unsubstituted, or mono- or di-substituted, wherein the substituents are independently selected from (C₁₋₄)alkyl, (C₁₋₄)alkoxy, -COOH, hydroxy, hydroxy-(C₁₋₃)alkyl, (C₃₋₅)cycloalkyl optionally containing one ring oxygen atom, or -NR^{N9}R^{N10} wherein **R^{N9}** and **R^{N10}** independently represent hydrogen, (C₁₋₃)alkyl, or hydroxy-(C₂₋₄)alkyl;
- 20 ➤ **R⁶** represents
 - (C₁₋₆)alkyl;
 - (C₁₋₄)alkoxy;
 - (C₁₋₃)fluoroalkyl;
 - 25 ➤ (C₁₋₃)fluoroalkoxy;
 - halogen;
 - hydroxy;
 - (C₃₋₆)cycloalkyl;
 - (C₃₋₆)cycloalkyl-oxy;
 - 30 ➤ hydroxy-(C₂₋₄)alkoxy;
 - -X²-NR^{N1}R^{N2}, wherein **X²** represents a direct bond; or **X²** represents -O-CH₂-CH₂*, wherein the asterisk indicates the bond that is linked to the -NR^{N1}R^{N2} group; and wherein **R^{N1}** and **R^{N2}** independently represent hydrogen, (C₁₋₄)alkyl, or (C₃₋₆)cycloalkyl;


- -S-R^{S2} wherein R^{S2} represents (C₁₋₄)alkyl, or (C₃₋₆)cycloalkyl optionally containing one ring oxygen atom;
- or Ar¹ represents 8- to 10-membered bicyclic heteroaryl; wherein said 8- to 10-membered bicyclic heteroaryl independently is mono-substituted with -(C₀₋₃)alkylene-COOR^{O2} wherein R^{O2} represents hydrogen or (C₁₋₄)alkyl;
- 5 • or Ar¹ represents a group of the structure (Ar-III):



which is selected from 2-oxo-2,3-dihydro-benzooxazol-6-yl, 3-methyl-2-oxo-2,3-dihydro-benzooxazol-5-yl, 1-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl, 2-oxo-1,2,3,4-tetrahydro-quinazolin-6-yl, 1-methyl-2-oxo-1,2,3,4-tetrahydro-quinazolin-6-yl, 1-oxo-1,2,3,4-tetrahydro-isoquinolin-6-yl, 1-methyl-2-oxo-1,2,3,4-tetrahydro-quinazolin-7-yl, and 1-oxo-1,2,3,4-tetrahydro-isoquinolin-7-yl;


or a pharmaceutically acceptable salt thereof.


3. A compound according to claims 1 or 2 for use according to claim 1; wherein **Ar**¹ represents a group selected from:



200


5






202

5




203

5




204



or a pharmaceutically acceptable salt thereof.

5. A compound of formula (III)




Formula (III)

wherein in compounds of the formula (III)

(R¹)_n represents one, two or three optional substituents on the phenyl ring (i.e. n represents the integer 0, 1, 2, or 3), wherein said substituents are independently selected from (C₁₋₃)alkyl, (C₁₋₃)alkoxy, -S-(C₁₋₃)alkyl, halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy, cyano, hydroxy, nitro, -CO-O-(C₁₋₃)alkyl, -NR^{N7}R^{N8} wherein R^{N7} and R^{N8} independently represent hydrogen or (C₁₋₄)alkyl, or R^{N7} and R^{N8} together with the nitrogen to which they are attached form a 4- to 6-membered carbocyclic ring;

and Ar¹ represents

- a phenyl group of the structure (Ar-I):



(Ar-I)

wherein

- R^ᵖ represents

➤ -X¹-CO-R^{ᵒ¹}, wherein


➤ X¹ represents a direct bond, (C₁₋₃)alkylene, -O-(C₁₋₃)alkylene-*, -NH-(C₁₋₃)alkylene-*, -CH=CH-, -NH-CO-*, or (C₃₋₅)cycloalkylene; wherein the asterisks indicate the bond that is linked to the -CO-R^{ᵒ¹} group; and

➤ R^{ᵒ¹} represents

- -OH;
- -O-(C₁₋₄)alkyl;
- -NH-SO₂-R^{S3} wherein R^{S3} represents (C₁₋₄)alkyl, (C₃₋₆)cycloalkyl wherein the (C₃₋₆)cycloalkyl optionally contains a ring oxygen atom, (C₃₋₆)cycloalkyl-(C₁₋₃)alkylene

wherein the (C₃₋₆)cycloalkyl optionally contains a ring oxygen atom, (C₁₋₃)fluoroalkyl, or -NH₂;

- **HET¹**, wherein **HET¹** represents 5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl, or 3-oxo-2,3-dihydro-[1,2,4]oxadiazol-5-yl; or
- 5 ➤ **HET**, wherein **HET** represents a group selected from 1H-tetrazol-5-yl, 3-hydroxy-isoxazol-5-yl, 2-hydroxy-[1,3,4]oxadiazol-4-yl, 3-amino-isoxazol-5-yl, 2-amino-oxazol-5-yl, 5-amino-[1,3,4]thiadiazol-2-yl, 5-methylamino-[1,3,4]thiadiazol-2-yl, 5-amino-[1,2,4]oxadiazol-3-yl;
- **R^{m1}** represents
 - (C₁₋₆)alkyl;
 - 10 ➤ (C₁₋₄)alkoxy;
 - (C₁₋₃)fluoroalkyl;
 - (C₁₋₃)fluoroalkoxy;
 - halogen;
 - (C₃₋₆)cycloalkyl;
 - 15 ➤ (C₃₋₆)cycloalkyl-oxy;
 - hydroxy-(C₂₋₄)alkoxy; or
 - -S-**R^{s2}** wherein **R^{s2}** represents (C₁₋₄)alkyl, or (C₃₋₆)cycloalkyl optionally containing one ring oxygen atom;
- **R^{m2}** represents hydrogen, methyl, fluoro, or chloro; and
- 20 ▪ **R^{o1}** represents hydrogen;
- or **Ar¹** represents a 5-membered heteroaryl group of the structure (Ar-II):




wherein


- 25 ▪ **Y** represents CH or N;
- **R⁷** represents
 - -**X¹**-CO-**R^{o1}**, wherein
 - **X¹** represents a direct bond, (C₁₋₃)alkylene, -O-(C₁₋₃)alkylene-*, -NH-(C₁₋₃)alkylene-*, -CH=CH-, -NH-CO-*, or (C₃₋₅)cycloalkylene; wherein the asterisks indicate the bond that is linked to the -CO-
 - 30 **R^{o1}** group; and
 - **R^{o1}** represents


- -OH;
 - -O-(C₁₋₄)alkyl;
 - -NH-SO₂-R^{S3} wherein R^{S3} represents (C₁₋₄)alkyl, (C₃₋₆)cycloalkyl wherein the (C₃₋₆)cycloalkyl optionally contains a ring oxygen atom, (C₃₋₆)cycloalkyl-(C₁₋₃)alkylene wherein the (C₃₋₆)cycloalkyl optionally contains a ring oxygen atom, (C₁₋₃)fluoroalkyl, or -NH₂;
- 5
- HET¹, wherein HET¹ represents 5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl, or 3-oxo-2,3-dihydro-[1,2,4]oxadiazol-5-yl; or
 - HET, wherein HET represents a group selected from 1H-tetrazol-5-yl, 3-hydroxy-isoxazol-5-yl, 2-hydroxy-[1,3,4]oxadiazol-4-yl, 3-amino-isoxazol-5-yl, 2-amino-oxazol-5-yl, 5-amino-[1,3,4]thiadiazol-2-yl, 5-methylamino-[1,3,4]thiadiazol-2-yl, 5-amino-[1,2,4]oxadiazol-3-yl;
- 10
- R⁶ represents
 - (C₁₋₆)alkyl;
 - (C₁₋₄)alkoxy;
 - 15 ➤ (C₁₋₃)fluoroalkyl;
 - (C₁₋₃)fluoroalkoxy;
 - halogen;
 - (C₃₋₆)cycloalkyl;
 - (C₃₋₆)cycloalkyl-oxy;
 - 20 ➤ hydroxy-(C₂₋₄)alkoxy; or
 - -S-R^{S2} wherein R^{S2} represents (C₁₋₄)alkyl, or (C₃₋₆)cycloalkyl optionally containing one ring oxygen atom;

or a pharmaceutically acceptable salt thereof.

- 25 6. A compound according to claim 5; wherein Ar¹ represents a group selected from








- 5 or a pharmaceutically acceptable salt thereof.

7. A compound according to claims 5 or 6; wherein $(R^1)_n$ represents one, two or three substituents on the phenyl ring, wherein said substituents are independently selected from (C_{1-3}) alkyl, (C_{1-3}) alkoxy, $-S-(C_{1-3})$ alkyl, halogen, (C_{1-3}) fluoroalkyl, (C_{1-3}) fluoroalkoxy, cyano, or hydroxy;

- 10 or a pharmaceutically acceptable salt thereof.

8. A compound according to claims 5 or 6; wherein the fragment




represents a group selected from phenyl, 4-bromo-phenyl, 3-bromo-phenyl, 2-bromo-phenyl, 4-chloro-phenyl, 3-chloro-phenyl, 2-chloro-phenyl, 4-fluoro-phenyl, 3-fluoro-phenyl, 2-fluoro-phenyl, 2-methyl-phenyl, 3-methyl-phenyl, 4-methyl-phenyl, 4-hydroxy-phenyl, 4-methoxy-phenyl, 3-methoxy-phenyl, 2-methoxy-phenyl, 4-bromo-2-methyl-phenyl, 4-bromo-3-methyl-phenyl, 2,4-dimethyl-phenyl, 3,4-dimethyl-phenyl, 2,4-dichloro-phenyl, 3,4-dichloro-phenyl, 2,6-difluoro-phenyl, 4-bromo-3-chloro-phenyl, 4-bromo-2-chloro-phenyl, 2-bromo-5-chloro-phenyl, 4-bromo-3-fluoro-phenyl, 4-bromo-2-fluoro-phenyl, 4-chloro-2,6-difluoro-phenyl, 3-chloro-2,6-difluoro-phenyl, 2-chloro-3,6-difluoro-phenyl, 2,4,6-trifluoro-phenyl, 4-bromo-2,5-difluoro-phenyl, 4-bromo-2,6-difluoro-phenyl, 4-

- 15

bromo-2-ethyl-phenyl, 4-bromo-5-fluoro-2-methyl-phenyl, 4-bromo-2-fluoro-5-methyl-phenyl, 3-hydroxy-4-methoxy-phenyl, 4-hydroxy-3-methoxy-phenyl, 3-chloro-4-methoxy-phenyl, 4-bromo-3-methoxy-phenyl, 3-bromo-4-methoxy-phenyl, 2-fluoro-4-methoxy-phenyl, 4-bromo-2-methoxy-phenyl, 5-bromo-2-methoxy-phenyl, 2-ethoxy-phenyl, 5-chloro-2-cyano-phenyl, 4-chloro-2-cyano-phenyl, 4-fluoro-2-cyano-phenyl, 4-chloro-2-methylamino-phenyl, 4-trifluoromethyl-phenyl, 3-trifluoromethyl-phenyl, 2-trifluoromethyl-phenyl, 2,5-dimethoxy-phenyl, 2,3-dimethoxy-phenyl, 2,4-dimethoxy-phenyl, 3,5-dimethoxy-phenyl, 3-(methoxy-carbonyl)-phenyl, 2-methoxy-5-(methylsulfanyl)-phenyl, 2-methoxy-4-(methylsulfanyl)-phenyl, 4-fluoro-2-ethoxy-phenyl, 4-bromo-2-ethoxy-phenyl, 2-ethyl-4-methoxy-phenyl, 2-methoxy-4,5-dimethyl-phenyl, 4-chloro-6-fluoro-2-methoxy-phenyl, 4-bromo-6-fluoro-2-methoxy-phenyl, 4-dimethylamino-2-fluoro-phenyl, 2-dimethylamino-4-bromo-phenyl, 4-chloro-2-nitro-phenyl, 2-fluoro-4-trifluoromethyl-phenyl, 4-bromo-2,6-dimethoxy-phenyl, 4-bromo-2-*n*-propoxy-phenyl, 4-bromo-2-trifluoromethoxy-phenyl, 4-bromo-2-(pyrrolidin-1-yl)-phenyl, 2-ethoxy-4-trifluoromethyl-phenyl, 3,4-dichloro-2-methyl-phenyl, 5-bromo-2-methylsulfanyl-phenyl, 2-fluoro-6-methoxy-phenyl, 2-methoxy-6-methyl-phenyl, 2-methoxy-4,6-dimethyl-phenyl, 4,5-difluoro-2-methoxy-phenyl, 2,6-difluoro-4-methoxy-phenyl, 4-difluoromethoxy-2-methoxy-phenyl, 4-difluoromethyl-5-fluoro-2-methoxy-phenyl, 2-methoxy-4-trifluoromethyl-phenyl, 4-difluoromethyl-2-methoxy-5-methyl-phenyl, 2-methoxy-4-trifluoromethoxy-phenyl, 2-fluoro-6-methoxy-4-trifluoromethyl-phenyl, 5-chloro-2-methoxy-4-trifluoromethyl-phenyl, and 2-difluoromethoxy-4-trifluoromethyl-phenyl;

or a pharmaceutically acceptable salt thereof.

9. A compound according to claims 5 or 6; wherein the fragment



represents a group selected from 4-bromo-phenyl, 4-chloro-phenyl, 4-methyl-phenyl, 2,4-dichloro-phenyl, 3,4-dichloro-phenyl, 2,6-difluoro-phenyl, 4-bromo-3-chloro-phenyl, 4-bromo-2-chloro-phenyl, 2-bromo-5-chloro-phenyl, 4-bromo-2-fluoro-phenyl, 4-chloro-2,6-difluoro-phenyl, 3-chloro-2,6-difluoro-phenyl, 2-chloro-3,6-difluoro-phenyl, 2,4,6-trifluoro-phenyl, 4-bromo-2,5-difluoro-phenyl, 4-bromo-2,6-difluoro-phenyl, 4-bromo-2-fluoro-5-methyl-phenyl, 4-hydroxy-3-methoxy-phenyl, 4-bromo-3-methoxy-phenyl, 2-fluoro-4-methoxy-phenyl, 4-bromo-2-methoxy-phenyl, 5-bromo-2-methoxy-phenyl, 2,5-dimethoxy-phenyl, 2,3-dimethoxy-phenyl, 2,4-dimethoxy-phenyl, 2-methoxy-4-(methylsulfanyl)-phenyl, 4-bromo-2-ethoxy-phenyl, 2-ethyl-4-methoxy-phenyl, 2-methoxy-4,5-dimethyl-phenyl, 4-chloro-6-fluoro-2-methoxy-phenyl, 4-bromo-2,6-dimethoxy-phenyl, 4-bromo-2-*n*-propoxy-phenyl, and 2-ethoxy-4-trifluoromethyl-phenyl;

or a pharmaceutically acceptable salt thereof.

10. A compound according to claim 5 selected from the group consisting of:
- 3-Fluoro-5-[6-(2-p-tolyl-ethylamino)-pyrimidin-4-yl]-thiophene-2-carboxylic acid;
4-[6-[2-(2-Methoxy-4-methylsulfanyl-phenyl)-ethylamino]-pyrimidin-4-yl]-2-methylsulfanyl-benzoic acid;
4-[6-[2-(2-Methoxy-4,5-dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl]-2-methylsulfanyl-benzoic acid;
5 3-Ethoxy-5-[6-[2-(2-methoxy-4-methylsulfanyl-phenyl)-ethylamino]-pyrimidin-4-yl]-thiophene-2-carboxylic acid;
3-Ethoxy-5-[6-[2-(2-methoxy-4,5-dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl]-thiophene-2-carboxylic acid;
2-Ethoxy-4-[6-[2-(2-methoxy-4,5-dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl]-benzoic acid;
3-(4-[6-[2-(4-Bromo-phenyl)-ethylamino]-pyrimidin-4-yl]-2-ethoxy-phenyl)-[1,2,4]oxadiazol-5(4H)-one;
3-(4-[6-((4-bromophenethyl)amino)pyrimidin-4-yl]-2-ethoxyphenyl)-[1,2,4]oxadiazol-5-ol;
10 4-[6-[2-(3,4-Dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl]-2-methylsulfanyl-benzoic acid;
4-[6-[2-(4-Bromo-2-fluoro-phenyl)-ethylamino]-pyrimidin-4-yl]-2-ethoxy-benzoic acid;
[2-(4-Bromo-2,6-difluoro-phenyl)-ethyl]-[6-[3-ethoxy-4-(1H-tetrazol-5-yl)-phenyl]-pyrimidin-4-yl]-amine;
N-(4-[6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl]-2-ethoxy-phenyl)-oxalamic acid;
5-[6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl]-4-chloro-3-ethoxy-thiophene-2-carboxylic acid;
15 5-[6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl]-3-methyl-thiophene-2-carboxylic acid;
5-[6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl]-3-ethyl-thiophene-2-carboxylic acid;
5-[6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl]-3-chloro-thiophene-2-carboxylic acid;
5-[6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl]-3-(2-hydroxy-ethoxy)-thiophene-2-carboxylic acid;
20 4-[6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl]-2-methylsulfanyl-benzoic acid;
4-[6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl]-2-isobutyl-benzoic acid;
4-[6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl]-2-difluoromethoxy-benzoic acid;
3-(5-[6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl]-3-ethoxy-thiophen-2-yl)-propionic acid;
3-(4-[6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl]-2-ethoxy-phenoxy)-propionic acid;
25 (E)-3-(5-[6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl]-3-ethoxy-thiophen-2-yl)-acrylic acid;
(5-[6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl]-3-ethoxy-thiophen-2-yl)-acetic acid;
(4-[6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl]-2-ethoxy-phenyl)-acetic acid;
5-[6-[2-(4-Bromo-phenyl)-ethylamino]-pyrimidin-4-yl]-3-ethoxy-thiophene-2-carboxylic acid;
3-Ethoxy-5-[6-[2-(4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl]-thiophene-2-carboxylic acid;
30 3-Ethoxy-5-[6-[2-(3-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl]-thiophene-2-carboxylic acid;
5-[6-(2-p-Tolyl-ethylamino)-pyrimidin-4-yl]-3-trifluoromethyl-thiophene-2-carboxylic acid;
5-[6-[2-(4-Chloro-2-nitro-phenyl)-ethylamino]-pyrimidin-4-yl]-3-ethoxy-thiophene-2-carboxylic acid;
5-[6-[2-(2,4-Dichloro-phenyl)-ethylamino]-pyrimidin-4-yl]-3-ethoxy-thiophene-2-carboxylic acid;
5-[6-[2-(3,4-Dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl]-3-ethoxy-thiophene-2-carboxylic acid;
35 5-[6-[2-(5-Bromo-2-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl]-3-ethoxy-thiophene-2-carboxylic acid;
5-[6-[2-(2,5-Dimethoxy-phenyl)-ethylamino]-pyrimidin-4-yl]-3-ethoxy-thiophene-2-carboxylic acid;

- 5-{6-[2-(2,4-Dimethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid;
5-{6-[2-(4-Chloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid;
3-(5-{6-[2-(4-Bromo-2-ethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
5 3-(5-{6-[2-(4-Bromo-2-ethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
3-(5-{6-[2-(4-Chloro-2-fluoro-6-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(5-{6-[2-(4-Chloro-2-fluoro-6-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
10 3-(5-{6-[2-(4-Bromo-2-fluoro-6-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(5-{6-[2-(4-Bromo-2-fluoro-6-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
3-(5-{6-[2-(4-Bromo-2,6-dimethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
15 3-(5-{6-[2-(4-Bromo-2,6-dimethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
3-(5-{6-[2-(4-Bromo-2-propoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
20 3-(5-{6-[2-(4-Bromo-2-propoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
3-(3-Ethoxy-5-{6-[2-(2-ethoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(3-Ethoxy-5-{6-[2-(2-ethoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
25 3-(3-Ethoxy-5-{6-[2-(2-fluoro-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(3-Ethoxy-5-{6-[2-(2-fluoro-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
3-(5-{6-[2-(2-Bromo-5-chloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
30 3-(5-{6-[2-(2-Bromo-5-chloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
3-(3-Ethoxy-5-{6-[2-(2-ethoxy-4-fluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(3-Ethoxy-5-{6-[2-(2-ethoxy-4-fluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
5-Chloro-2-((6-(4-ethoxy-5-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)thiophen-2-yl)pyrimidin-4-yl)amino)ethyl)benzonitrile;
35

- 5-Chloro-2-(2-{6-[4-ethoxy-5-(5-hydroxy-[1,2,4]oxadiazol-3-yl)-thiophen-2-yl]-pyrimidin-4-ylamino}-ethyl)-benzonitrile;
- 2-(2-{6-[4-Ethoxy-5-(5-hydroxy-[1,2,4]oxadiazol-3-yl)-thiophen-2-yl]-pyrimidin-4-ylamino}-ethyl)-5-fluorobenzonitrile;
- 5 2-(2-((6-(4-Ethoxy-5-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)thiophen-2-yl)pyrimidin-4-yl)amino)ethyl)-5-fluorobenzonitrile;
- 3-(5-{6-[2-(3-Chloro-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 3-(5-{6-[2-(3-Chloro-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 10 3-(3-Ethoxy-5-{6-[2-(2-ethyl-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 3-(3-Ethoxy-5-{6-[2-(2-ethyl-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 3-(5-{6-[2-(2-Chloro-3,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 15 3-(5-{6-[2-(2-Chloro-3,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 3-(3-Ethoxy-5-{6-[2-(2,4,6-trifluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 3-(3-Ethoxy-5-{6-[2-(2,4,6-trifluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 3-(3-Ethoxy-5-{6-[2-(2-ethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 3-(3-Ethoxy-5-{6-[2-(2-ethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 20 3-(5-{6-[2-(2,6-Difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 3-(5-{6-[2-(2,6-Difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 3-(5-{6-[2-(4-Chloro-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 3-(5-{6-[2-(4-Chloro-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 25 3-(5-{6-[2-(4-Bromo-3-chloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 3-(5-{6-[2-(4-Bromo-3-chloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 3-(5-{6-[2-(4-Bromo-2,5-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 30 3-(5-{6-[2-(4-Bromo-2,5-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 3-(5-{6-[2-(4-Bromo-3-fluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 3-(5-{6-[2-(4-Bromo-3-fluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 35 5(4H)-one;
- 3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

- 3-(5-{6-[2-(4-Bromo-5-fluoro-2-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 3-(5-{6-[2-(4-Bromo-5-fluoro-2-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 5 3-(5-{6-[2-(4-Bromo-3-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 3-(5-{6-[2-(4-Bromo-3-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 3-(5-{6-[2-(4-Bromo-2-fluoro-5-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 10 3-(5-{6-[2-(4-Bromo-2-fluoro-5-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 3-(5-{6-[2-(4-Bromo-3-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 3-(5-{6-[2-(4-Bromo-3-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 15 3-(5-{6-[2-(2,4-Dimethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 3-(5-{6-[2-(2,4-Dimethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 3-(3-Ethoxy-5-{6-[2-(4-hydroxy-3-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 3-(3-Ethoxy-5-{6-[2-(4-hydroxy-3-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 20 3-(5-{6-[2-(2,3-Dimethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 3-(5-{6-[2-(2,3-Dimethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 3-(5-{6-[2-(5-Bromo-2-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 3-(5-{6-[2-(5-Bromo-2-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 25 3-(5-{6-[2-(3,4-Dichloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 3-(5-{6-[2-(3,4-Dichloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 3-(5-{6-[2-(2,4-Dichloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 3-(5-{6-[2-(2,4-Dichloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 3-(5-{6-[2-(4-Bromo-2-chloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 30 one;
- 3-(5-{6-[2-(4-Bromo-2-chloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 3-(5-{6-[2-(4-Bromo-2-fluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- one;
- 3-(5-{6-[2-(4-Bromo-2-fluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 35 3-(5-{6-[2-(4-Bromo-2-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

- 3-(5-{6-[2-(4-Bromo-2-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
3-(5-{6-[2-(4-Bromo-2-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(5-{6-[2-(4-Bromo-2-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
5 3-(5-{6-[2-(4-Bromo-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(5-{6-[2-(4-Bromo-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
[2-(4-Bromo-phenyl)-ethyl]-{6-[4-ethoxy-5-(1H-tetrazol-5-yl)-thiophen-2-yl]-pyrimidin-4-yl}-amine;
3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-trifluoromethyl-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
10 3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-trifluoromethyl-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
15 2-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-4-ethoxy-thiazole-5-carboxylic acid;
2-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-4-ethyl-thiazole-5-carboxylic acid;
3-(2-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-4-ethoxy-thiazol-5-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(2-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-4-ethoxy-thiazol-5-yl)-[1,2,4]oxadiazol-5-ol;
20 3-(2-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-4-ethyl-thiazol-5-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(2-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-4-ethyl-thiazol-5-yl)-[1,2,4]oxadiazol-5-ol;
5-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,3,4]oxadiazol-2-ol;
5-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,3,4]oxadiazol-25 2(3H)-one;
N-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carbonyl)-methanesulfonamide;
5-(6-((4-bromo-2,6-difluorophenethyl)amino)pyrimidin-4-yl)-3-ethoxy-N-sulfamoylthiophene-2-carboxamide;
3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-2-methyl-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
30 [1,2,4]oxadiazol-5(4H)-one;
3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-2-methyl-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
3-(5-{6-[2-(4-Bromo-phenyl)-ethylamino]-2-methyl-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
35 3-(5-{6-[2-(4-Bromo-phenyl)-ethylamino]-2-methyl-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

- 3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-isopropoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-isopropoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 5 4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-(2-hydroxy-ethoxy)-benzoic acid;
4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-propyl-benzoic acid;
4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-propoxy-benzoic acid;
4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-ethylsulfanyl-benzoic acid;
4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-cyclobutoxy-benzoic acid;
- 10 4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-butoxy-benzoic acid;
4-{6-[2-(4-Bromo-2-ethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-2-ethoxy-benzoic acid;
5-{6-[2-(2,6-Difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethyl-thiophene-2-carboxylic acid;
3-Ethoxy-5-{6-[2-(o-tolyl-ethylamino)-pyrimidin-4-yl]-thiophene-2-carboxylic acid};
3-Fluoro-5-{6-[2-(4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;
- 15 3-Ethoxy-5-{6-[2-(4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;
5-{6-[2-(2,4-Dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-trifluoromethyl-thiophene-2-carboxylic acid;
5-{6-[2-(3-Bromo-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid;
3-Ethoxy-5-{6-[2-(3-methoxycarbonyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;
3-(5-{6-[2-(3,4-Dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 20 3-(5-{6-[2-(3,4-Dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
3-(3-Ethoxy-5-{6-[2-(2-fluoro-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(3-Ethoxy-5-{6-[2-(2-fluoro-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 25 3-(3-Ethoxy-5-{6-[2-(3-hydroxy-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(3-Ethoxy-5-{6-[2-(3-hydroxy-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
3-(5-{6-[2-(3-Chloro-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
- 30 3-(5-{6-[2-(3-Chloro-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
3-(5-{6-[2-(4-Dimethylamino-2-fluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one; and
3-(5-{6-[2-(4-Dimethylamino-2-fluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
- 35 or a pharmaceutically acceptable salt thereof.

11. A compound according to claim 5 selected from the group consisting of:
- 5-(4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-methoxy-phenyl)-isoxazol-3-ol;
5-(4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-methoxy-phenyl)-isoxazol-3(2H)-one;
- 5 5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-methoxy-thiophene-2-carboxylic acid;
5-{6-[2-(3,4-Dichloro-2-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid;
2-Cyclobutoxy-4-{6-[2-(4-difluoromethyl-5-fluoro-2-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-benzoic acid;
5-{6-[2-(4-Difluoromethyl-5-fluoro-2-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid;
- 10 2-Cyclobutoxy-4-{6-[2-(2-methoxy-4,5-dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-benzoic acid;
3-Ethoxy-5-{6-[2-(2-methoxy-4,6-dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;
2-Ethoxy-4-{6-[2-(2-ethoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-benzoic acid ;
4-{6-[2-(2-Ethoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-2-methylsulfanyl-benzoic acid;
(2-Ethoxy-4-{6-[2-(2-ethoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-phenyl)-acetic acid;
- 15 3-Ethoxy-5-{6-[2-(2-ethoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;
5-{6-[2-(4-Difluoromethoxy-2-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid;
3-Ethoxy-5-{6-[2-(2-fluoro-6-methoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;
- 3-(4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-ethoxy-phenyl)-[1,2,4]oxadiazol-5(4H)-;
- 20 3-(4-{6-[2-(4-bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-ethoxy-phenyl)-[1,2,4]oxadiazol-5-ol;
(4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-chloro-6-ethyl-phenyl)-acetic acid;
(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethyl-thiophen-2-yl)-acetic acid;
5-(4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-ethoxy-phenyl)-isoxazol-3-ol;
5-(4-{6-((4-Bromo-2,6-difluorophenethyl)amino)pyrimidin-4-yl}-2-ethoxyphenyl)isoxazol-3(2H)-one;
- 25 3-(5-{6-[2-(5-Bromo-2-methylsulfanyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(5-{6-[2-(5-Bromo-2-methylsulfanyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-propyl-thiophen-2-yl)-acetic acid;
- 30 (5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-difluoromethoxy-thiophen-2-yl)-acetic acid;
4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-butoxy-6-fluoro-benzoic acid;
3-Ethoxy-5-{6-[2-(2-methoxy-6-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;
4-{6-[2-(2-Ethoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-2-propyl-benzoic acid;
4-{6-[2-(4-Difluoromethoxy-2-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-2-methylsulfanyl-benzoic acid,
- 35 4-{6-[2-(2,6-Difluoro-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-2-methylsulfanyl-benzoic acid;
4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-isobutoxy-benzoic acid;

- 4-[6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl]-2-cyclopropoxy-benzoic acid;
 N-(4-[6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl]-2-ethoxy-benzoyl)-methanesulfonamide;
 5-[6-[2-(5-Chloro-2-methoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl]-3-ethoxy-thiophene-2-carboxylic acid;
 5 3-Ethoxy-5-[6-[2-(2-methoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl]-thiophene-2-carboxylic acid;
 3-Ethoxy-5-[6-[2-(2-methoxy-4-trifluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl]-thiophene-2-carboxylic acid;
 5-[6-[2-(2-Difluoromethoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl]-3-ethoxy-thiophene-2-carboxylic acid; and
 3-(2-Ethoxy-4-[6-[2-(2-methoxy-4,5-dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl]-phenoxy)-propionic acid;
 10 or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition comprising, as active principle, a compound according to any one of claims 5 to 11, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.
13. A compound according to any one of claims 5 to 11, or a pharmaceutically acceptable salt thereof, for use as
 15 a medicament.
14. A compound according to any one of claims 5 to 11, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of diseases selected from the group consisting of cancer; pain; endometriosis; autosomal dominant polycystic kidney disease; acute ischemic syndromes in atherosclerotic patients; pneumonia; and neurodegenerative diseases; or for use in the control of female fertility.
- 20 15. Use of a compound according to any one of claims 5 to 11, or of a pharmaceutically acceptable salt thereof, in the prevention or treatment of a cancer selected from melanoma; lung cancer; bladder cancer; renal carcinomas; gastro-intestinal cancers; endometrial cancer; ovarian cancer; cervical cancer; and neuroblastoma.
16. A compound according to any one of claims 5 to 11, or a pharmaceutically acceptable salt thereof, for use in the preparation of a medicament for the prevention or treatment of diseases selected from the group consisting of
 25 cancer; pain; endometriosis; autosomal dominant polycystic kidney disease; acute ischemic syndromes in atherosclerotic patients; pneumonia; and neurodegenerative diseases; or for the control of female fertility.
17. A compound according to any one of claims 5 to 11, or a pharmaceutically acceptable salt thereof, for use in the treatment of a cancer, wherein said cancer is treated by modulating an immune response comprising a reactivation of the immune system in the tumor; wherein said compound is optionally used in combination with one
 30 or more chemotherapy agents and / or radiotherapy and / or targeted therapy.
18. A method of modulating an immune response in a subject having a tumor, comprising the administration of an effective amount of a compound of formula (I) as defined in claim 1, or of a compound of formula (III) according to any one of claims 5 to 11; or of a pharmaceutically acceptable salt thereof; wherein said effective amount reactivates the immune system in the tumor of said subject.

19. A method of prophylaxis or treatment of cancer; pain; endometriosis; autosomal dominant polycystic kidney disease; acute ischemic syndromes in atherosclerotic patients; pneumonia; and neurodegenerative diseases; or for the control of female fertility; comprising administering to a subject in need thereof a compound of formula (III) according to any one of claims 5 to 11, or a pharmaceutically acceptable salt thereof.